Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Normothermic Ex Vivo Lung Perfusion (EVLP) For An Improved Assessment of Donor Lungs For Transplantation (HELP)

This study has been completed.
Information provided by:
XVIVO Perfusion Identifier:
First received: August 25, 2010
Last updated: November 12, 2010
Last verified: November 2010
The use of ex vivo lung perfusion (EVLP) will allow for a secondary evaluation technique for donor lungs that fail to meet standard acceptability criteria. This advanced assessment might lead to increased utilization rates of donor lungs and improved outcomes after lung transplantation.

Condition Intervention Phase
Lung Transplantation
Drug: Ex vivo lung perfusion with Steen Solution™
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Normothermic Ex Vivo Lung Perfusion (EVLP) For An Improved Assessment of Donor Lungs For Transplantation

Resource links provided by NLM:

Further study details as provided by XVIVO Perfusion:

Primary Outcome Measures:
  • PGD scores in the first 72 hours after lung transplantation. [ Time Frame: 72 hours ]
    Immediate lung function is one of the key factors in determining the impact of donor lung quality, therefore the PGD score within 72 hrs was selected as the primary endpoint.

  • 30 day Mortality [ Time Frame: 30 days ]
    Mortality at 30 days post transplant

Secondary Outcome Measures:
  • Extra-corporeal membrane oxygenation use [ Time Frame: 30 days ]
    If the patient needed to be placed on extra-corporeal membrane oxygenation after transplantation.

  • Bronchial complications [ Time Frame: 30 days ]
    To see if there was an increased risk for bronchial complications

  • Ventilator duration [ Time Frame: 30 days ]
    How long was the patient on the ventilator after lung transplantation and was there an increased time on ventilator for the patient after EVLP.

  • Intensive Care Unit length of stay [ Time Frame: 30 days ]
  • Hospital length of stay [ Time Frame: 30 days ]
    Time in the hospital

Enrollment: 22
Study Start Date: August 2008
Study Completion Date: February 2010
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: EVLP Group
EVLP Group are those recipient lung transplant patients that received donor lungs that had been placed on the ex vivo lung perfusion system with Steen Solution™ .
Drug: Ex vivo lung perfusion with Steen Solution™
The circuit is primed with 2,000cc Steen Solution™. At one hour of EVLP, 500 cc of circulated perfusate was removed and replenished with 500 cc of fresh perfusate. After that, 250 cc of perfusate was exchanged every hour.

Detailed Description:

Human donor lungs that do not meet the standard clinical criteria for donor lung utilization but fit into the study inclusion criteria will be retrieved from the donor using current donor lung retrieval techniques.

These lungs will be brought to the study transplant center to be re-assessed by the transplant team. The lungs will be physiologically assessed during ex vivo perfusion with Steen Solution. Perfusion of these lungs will be performed using Steen solution with the addition of methylprednisolone, heparin and antibiotics. With respect to the decision of lung utilization those organs with a delta pO2 (Δ pO2 = Pulmonary vein pO2 - pulmonary artery pO2) during ex vivo perfusion assessment > 350mmHg, good lung compliance, and a favorable opinion of the transplant surgeon will be considered transplantable. Lungs will be excluded for transplantation: if the Δ pO2 is less than 350mmHg or if they demonstrate >10% deterioration in any of the following functional parameters: pulmonary vascular resistance (PVR), dynamic compliance or airway pressures. Lungs will also be excluded if they are deemed unsuitable based on the clinical judgment of the lung transplant surgeon.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria for donor lung:

  1. Recipient to undergo a single or bilateral Lung Transplantation
  2. Last donor PaO2/FiO2 ≤ 300mmHg
  3. Poor oxygenation and/or poor lung compliance is the primary reason for unsuitability
  4. Absence of pneumonia, persistent purulent secretion on bronchoscopy or significant mechanical trauma

Exclusion Criteria:

  1. Infection
  2. Aspiration
  3. Significant mechanical lung injury - contusion
  4. Infectious diseases : HIV, Hepatitis B and C, HTLV & Syphilis
  5. Malignancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01190059

Canada, Ontario
Toronto General Hospital
Toronto, Ontario, Canada, M5G 1Z5
Sponsors and Collaborators
XVIVO Perfusion
Principal Investigator: Shaf Keshavjee, MD,MSc,FRCSC University of Toronto-Toronto General Hospital
  More Information

D.M. Karamanou, H.R. Walden, S. Bean, et al. The Effect of Ex-Vivo Perfusion on the Inflammatory Profile of the Donor Lung. J Heart Lung Transplant 2010:Vol. 29, Issue 2, Supplement, Page S165.

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Dr. Shaf Keshavjee, University of Toronto-Toronto General Hospital Identifier: NCT01190059     History of Changes
Other Study ID Numbers: VIT-001-TOR
139150 ( Other Identifier: Health Canada )
Study First Received: August 25, 2010
Last Updated: November 12, 2010

Keywords provided by XVIVO Perfusion:
Lung Transplantation
Transplantation Lung

Additional relevant MeSH terms:
Pharmaceutical Solutions processed this record on April 28, 2017